Skip to main content

Market Overview

Ironwood Pharmaceuticals Falls 6% Following Disappointing Phase 2a Study

Share:

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) fell more than 6 percent early Tuesday morning after the company announced disappointing top-line data from a Phase 2a study.

Ironwood Pharmaceuticals stated that top line data from its Phase 2a clinical study of IW-9179 in diabetic gastroparesis did not meaningfully reduce the severity of symptoms among patients when compared to a placebo. The company did, however, add that its therapy was generally well-tolerated with the most common adverse event being diarrhea, which was mostly mild to moderate in nature.

Related Link: Betting On The Pfizer-Allergan Merger? You Now Have A 35% Arbitrage Opportunity After New Treasury Fears

Irownwood Pharmaceuticals added that it will discontinue development of its therapy and plans on focusing on ongoing programs in three key franchises, including irritable bowel syndrome, vascular and fibrotic disease and refractory gastroesophageal reflux disease.

"Our mission is to bring innovative medicines to patients in need, and exploratory trials are designed to help us identify the investigational medicines and appropriate indications with the most potential to help patients," said Mark Currie, Ph.D., chief scientific officer and president of research and development at Ironwood. "While these data indicate IW-9179 does not warrant advancement for gastroparesis, we recognize gastroparesis as a severely underserved disorder, and we want to extend our gratitude to the patients and health care professionals who participated in this study."

 

Related Articles (IRWD)

View Comments and Join the Discussion!

Posted-In: Diabetic Gastroparesis Ironwood PharmaceuticalsBiotech News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com